India offers incentives to domestic drugmakers for APIs; After PhIII trials, Taiho licenses Arokaris in Japan
India has been dependent on the import of active pharmaceutical ingredients to manufacture its drugs. But thanks to a a recent government initiative, 35 of those will now be manufactured in the country.
India depends on imports for 90% of its APIs, Mansukh Mandaviya, the Minister of Health & Family Welfare and Chemicals and Fertilizers told reporters this week. But thanks to a production-linked incentive scheme brought on by the government, in-country pharmas can receive payments over the next six years for making formulations, biopharmaceuticals, active pharmaceutical ingredients, key starting material, drug intermediates, and in vitro diagnostic medical devices.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.